title: Sentinel node detection by lymphoscintigraphy and sentinel lymph node biopsy in vulvar melanoma.
abstract: OBJECTIVE
  Vulvar melanoma is a rare malignant tumour. Its surgical excision is the mainstay of treatment whilst the surgical management of regional lymph nodes remains controversial; on the contrary elective inguinofemoral lymphadenectomy causes considerable morbidity. Lymphoscintigraphy (LS) and sentinel lymph node biopsy (SLNB) are accurate staging procedures of lymph node status in breast cancer and cutaneous melanoma patients. In this retrospective paper we report our experience of LS and SLNB in vulvar melanoma patients.
  
  
  METHODS
  Twenty-two consecutive patients with a diagnosis of vulvar melanoma were treated at our institute: patients with clinically positive groin nodes or with previous surgery on the primary tumour were excluded. Twelve were selected for our analysis. All patients underwent sentinel lymph node localization with LS the day before surgery and the surgical procedure of SLNB associated with radical surgery.
  
  
  RESULTS
  Six patients had metastatic SLNB and in five of six (83.3%) it was the only positive node. In the other six patients SLNB was negative for metastatic disease. No skip metastases were observed. In SLNB negative patients the mean Breslow thickness was 2.06 mm (range: 0.60-7.10) and only one patient showed a high Breslow thickness (patient 8). In SLNB positive patients the mean Breslow thickness was 4.33 mm (1.8-6.0).
  
  
  CONCLUSIONS
  Our data indicate that, even in vulvar melanoma, the sentinel lymph node pathological status predicts the pathological status of the remaining groin nodes and suggests that elective groin dissection can be spared in cases of a negative SLNB. Breslow thickness (<1 mm) was not predictive of negative nodes.
authors.affiliation: Nuclear Medicine Division, European Institute of Oncology, Via G. Ripamonti 435, 20141 Milan, Italy. giuseppe.trifiro@ieo.it
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Trifirò
authors.forename: Laura L
authors.initials: LL
authors.lastname: Travaini
authors.forename: Francesca
authors.initials: F
authors.lastname: Sanvito
authors.forename: Monica
authors.initials: M
authors.lastname: Pacifici
authors.forename: Andrew
authors.initials: A
authors.lastname: Mallia
authors.forename: Mahila E
authors.initials: ME
authors.lastname: Ferrari
authors.forename: Andrea
authors.initials: A
authors.lastname: Vertua
authors.forename: Angelo
authors.initials: A
authors.lastname: Maggioni
authors.forename: Giovanni
authors.initials: G
authors.lastname: Paganelli
authors.forename: Mario G
authors.initials: MG
authors.lastname: Sideri
mesh_terms: D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis / Q000000981:diagnostic imaging* / Q000473:pathology; D008545:Melanoma / Q000000981:diagnostic imaging / Q000473:pathology / Q000556:secondary* / Q000601:surgery; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D021701:Sentinel Lymph Node Biopsy / Q000379:methods*; D013668:Technetium Tc 99m Aggregated Albumin; D014846:Vulvar Neoplasms / Q000473:pathology* / Q000601:surgery
chemical_list: D019275:Radiopharmaceuticals; D013668:Technetium Tc 99m Aggregated Albumin; C083602:technetium Tc 99m nanocolloid